- Home
- BB vs NAMS Comparison
BB vs NAMS Comparison
Compare BB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- NAMS
- Stock Information
- Founded
- BB 1984
- NAMS 2019
- Country
- BB Canada
- NAMS Netherlands
- Employees
- BB N/A
- NAMS N/A
- Industry
- BB
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BB
- NAMS Health Care
- Exchange
- BB Nasdaq
- NAMS Nasdaq
- Market Cap
- BB 2.3B
- NAMS 2.2B
- IPO Year
- BB 1997
- NAMS N/A
- Fundamental
- Price
- BB $3.96
- NAMS $18.11
- Analyst Decision
- BB Buy
- NAMS Strong Buy
- Analyst Count
- BB 7
- NAMS 6
- Target Price
- BB $4.43
- NAMS $42.83
- AVG Volume (30 Days)
- BB 13.8M
- NAMS 694.5K
- Earning Date
- BB 06-25-2025
- NAMS 05-08-2025
- Dividend Yield
- BB N/A
- NAMS N/A
- EPS Growth
- BB N/A
- NAMS N/A
- EPS
- BB N/A
- NAMS N/A
- Revenue
- BB $534,900,000.00
- NAMS $47,140,000.00
- Revenue This Year
- BB N/A
- NAMS N/A
- Revenue Next Year
- BB $9.15
- NAMS N/A
- P/E Ratio
- BB N/A
- NAMS N/A
- Revenue Growth
- BB N/A
- NAMS 586.97
- 52 Week Low
- BB $2.01
- NAMS $14.06
- 52 Week High
- BB $6.24
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BB 57.04
- NAMS 47.80
- Support Level
- BB $3.73
- NAMS $16.79
- Resistance Level
- BB $4.19
- NAMS $19.58
- Average True Range (ATR)
- BB 0.16
- NAMS 0.94
- MACD
- BB 0.02
- NAMS -0.12
- Stochastic Oscillator
- BB 48.91
- NAMS 47.07
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.